What is the primary treatment modality for Kawasaki disease?

Kawasaki disease is primarily treated with intravenous immunoglobulin (IVIG) as it plays a critical role in reducing inflammation and preventing coronary artery complications, which are significant concerns in this condition. The administration of IVIG helps to decrease the risk of coronary artery aneurysms, which can occur due to the vasculitis that Kawasaki disease causes in children.

In addition to IVIG, aspirin is often used to address inflammation and prevent clot formation, particularly when there are cardiovascular risks. The effectiveness of IVIG in attenuating the inflammatory response and its proven efficacy in reducing the incidence of coronary artery abnormalities make it the cornerstone of treatment for Kawasaki disease. This targeted approach is essential in improving outcomes for affected children.

Other options like antibiotics and anticoagulants do not address the underlying cause of the disease, while immunosuppressants are generally not required for treating Kawasaki disease in acute settings.